Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

著者: Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl D. Lewis, Светлана Проценко, Rodrigo Perez Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Georgy M. Manikhas, Yibing Yan, Kuan-Chieh Huang, Anne Uyei, Virginia McNally, Grant A. McArthur, Paolo A. Ascierto - The Lancet 2020 被引用: 650